A concentrated preparation of antibodies from thousands of healthy donors — used to quiet chronic inflammation, restore immune balance, and support the body's capacity for renewal.
Book a Free ConsultationIntravenous immunoglobulin — IVIG — is a purified preparation of antibodies pooled from thousands of healthy blood donors. It has been FDA-approved for decades in primary immunodeficiencies and a range of autoimmune and neurological conditions, including Guillain-Barré syndrome, immune thrombocytopenia, CIDP, and Kawasaki disease.
Beyond these established uses, IVIG’s immunomodulatory properties have made it an active area of research in chronic inflammatory conditions, post-infectious syndromes, and — most recently — biological aging. At Global Apheresis, IVIG is offered both as a complement to therapeutic plasma exchange and as a standalone infusion therapy for select patients.
The body sometimes produces antibodies that mistakenly attack its own tissues. IVIG introduces a broad mix of well-functioning antibodies that can distract, neutralize, and outcompete these misdirected ones — interrupting cycles of autoimmune damage.
IVIG activates inhibitory receptors on immune cells, signaling them to reduce their activity. It also blocks certain acceleratory signals that keep the immune response in an elevated, pro-inflammatory state — effectively resetting the immune system's threshold.
In aging and post-infectious states, the immune system can remain stuck in a low-grade inflammatory mode — a phenomenon known as "inflammaging." IVIG's anti-inflammatory properties help reduce circulating pro-inflammatory molecules, creating conditions more favorable to tissue repair and recovery.
By providing a diverse library of functional antibodies and promoting regulatory T cell activity, IVIG helps restore a more balanced, responsive immune state — one associated with healthier aging and better recovery from illness.
In a landmark 2025 multi-omics study published in Aging Cell (Fuentealba M, Kiprov D, et al., Buck Institute), researchers examined the biological age effects of therapeutic plasma exchange combined with IVIG. Using 35 epigenetic clocks, participants receiving biweekly TPE plus IVIG demonstrated an average reduction in biological age of approximately 2.61 years — roughly twice the benefit observed with TPE alone.
IVIG’s role as an immunomodulator — reducing chronic inflammation and supporting immune recalibration — is believed to amplify the regenerative effects of plasma exchange.
IVIG has a well-established record in autoimmune and inflammatory neurological conditions. Its immunomodulatory effects have also been explored in post-infectious syndromes including PANS/PANDAS, post-Lyme immune dysregulation, and post-COVID immune sequelae — conditions in which persistent immune dysregulation, rather than active infection, drives ongoing symptoms.
Evidence in these areas ranges from robust (PANS/PANDAS, CIDP) to emerging (post-COVID subgroups), and Global Apheresis evaluates each patient individually.
Adults seeking to address the inflammatory drivers of aging — especially those who are already undergoing or considering therapeutic plasma exchange.
Patients with persistent immune dysregulation following infection, including Long COVID, PANS/PANDAS, and post-Lyme conditions where the immune system has not fully recalibrated.
Individuals with documented autoimmune activity — particularly those with autoantibody-driven neurological or systemic inflammation — for whom IVIG's immunomodulatory effects may reduce disease burden.
Patients already receiving therapeutic plasma exchange who wish to further enhance outcomes. Clinical research suggests the TPE + IVIG combination offers measurably greater biological age benefits than either therapy alone.
IVIG is administered only after a thorough medical evaluation. Not all patients are appropriate candidates. Most consultations begin as telehealth visits.
All IVIG candidates begin with a medical consultation — typically by telehealth — to review health history, current medications, immune markers, and treatment goals. Dr. Kiprov or Dr. Green will determine whether IVIG is appropriate as a standalone therapy, in combination with TPE, or not at all for your situation.
IVIG is administered through a standard peripheral IV. No central line or apheresis machine is required. You'll be comfortably seated in our infusion suite for the duration of the session.
The infusion typically takes 1–2 hours depending on dose. Vital signs are monitored throughout. Most patients read, rest, or work quietly during treatment.
All patients leave the same day. Some mild, transient effects — such as headache or fatigue — can occur and typically resolve within 24 hours.
For longevity and post-infectious indications, IVIG is often administered monthly or biweekly, sometimes in coordination with TPE sessions. Your treatment schedule is individualized based on your clinical picture and response.
Whether you’re exploring IVIG as a standalone therapy or as part of a combined approach with TPE, we’ll start with a thorough consultation to determine whether it’s right for you.
Book a Free Consultation